Study S002803

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT07351058
Acronym: Enith2
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: RECRUITING
Enrollment: 1600
Start: 2026-03-23
Primary completion: 2028-08-07
Lead sponsor: Hoffmann-La Roche
Conditions: Obesity or Overweight; Type 2 Diabetes Mellitus
Interventions: COMBINATION_PRODUCT:Placebo; COMBINATION_PRODUCT:Enicepatide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: CTIS:2025-523106-32-00; NIH:2025

Registered primary outcomes

Percent (%) Change from Baseline in Body Weight at Week 72 [Baseline through Week 72]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.